NCT06932523 - A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals | Biotech Hunter

Enrollment

645

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions

Herpes Zoster (HZ)

Interventions

BIOLOGICAL

Recombinant herpes zoster vaccine with low-dose adjuvant

Candidate 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule

BIOLOGICAL

Recombinant herpes zoster vaccine with high-dose adjuvant

Candidate 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule

BIOLOGICAL

Low-dose adjuvant

Adjuvant control 1, Dose Level 1, Intramuscular injection, 0, 2 months schedule

BIOLOGICAL

High-dose adjuvant

Adjuvant control 2, Dose Level 2, Intramuscular injection, 0, 2 months schedule

BIOLOGICAL

Shingrix (GSK)

Positive control, Intramuscular injection, 0, 2 months schedule

BIOLOGICAL

Normal Saline

Placebo control, Intramuscular injection, 0, 2 months schedule

All Listed Sponsors

lead

Shanghai Institute Of Biological Products

INDUSTRY